Melinta Therapeutics
Top View
- What's Inside
- UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
- Declaration of Disclosure Faculty Disclosures
- Manufacturer's W/Start/End Dates and Sc Ind
- Active Labelers Run Date : Aug 26, 2021
- Manufacturers and Wholesalers Street City ST Zip Submitted Under
- Antibiotics in the Clinical Pipeline in October 2019
- Rebateable Manufacturers
- Companies in Scope for the 2020 Antimicrobial Resistance Benchmark – 30 Companies Table 3 LARGE RESEARCH-BASED PHARMACEUTICAL COMPANIES
- Customer Rebate List Covering
- Melinta and Cempra Name Industry Leader Daniel Wechsler As President and Chief Executive Officer of the Combined Company
- Looking-For-Solutions-To-The-Pitfalls-Of
- CY 2017 CDER Drug and Biologic Calendar Year Priority Approvals As of December 31, 2017
- 2018 Healthcare Preliminary Agenda 12.13.17 EC
- Microbe 2016 Disclosures Listed by Session
- Antibiotics (Injectable) PA Policy Page 2
- List of Issuers with No Outstanding Past-Due Share of the Issuer Accounting Support Fee
- Registered Drug Distribution Agents, Manufacturers Wholesalers As of 2/19/21